# Retatrutide Muscle Loss: 7 Things the Research Shows

**By TelosRX Editorial Team** · 2026-11-20

**Retatrutide muscle loss is real but not unusual. In trial scans, most weight lost was fat, and lean mass fell in line with other obesity drugs. Retatrutide is still investigational. [TelosRX](https://telosrx.com) breaks down what the data shows.**

Search interest in "does retatrutide cause muscle loss" has climbed this month. That makes sense. Retatrutide posts some of the largest weight reductions seen in obesity trials so far.

Bigger weight loss raises a fair question. How much of it is fat, and how much is muscle? Here are seven things the research on retatrutide muscle loss actually shows, plus what you can do about it on any GLP-1 plan.

## Retatrutide Muscle Loss at a Glance

Start with the short version. The table pulls the headline body-composition numbers from published trials and a 2025 review.

| Medication | Trial length | Average weight change | Share of loss that was lean mass |
| --- | --- | --- | --- |
| Semaglutide 2.4 mg (STEP 1) | 68 weeks | about −14.9% | about 39% |
| Tirzepatide 15 mg (SURMOUNT-1) | 72 weeks | about −20.9% | about 24% |
| Retatrutide 12 mg (type 2 diabetes substudy) | 36 weeks | about −16.9% | about 33% |
| Retatrutide 12 mg (Phase 2 obesity trial) | 48 weeks | about −22.8% | not reported |

Figures come from Table 1 of a [2025 review in the World Journal of Diabetes](https://pmc.ncbi.nlm.nih.gov/articles/PMC12444289/). Trials used different people, doses and lengths. So read this as context, not a head-to-head ranking.

## 1\. Retatrutide Is a Triple Agonist, and Still Investigational

Retatrutide acts on three hormone receptors: GIP, GLP-1 and glucagon. Semaglutide hits one. Tirzepatide hits two. The glucagon piece is thought to raise energy use and push the liver to burn more fat.

Retatrutide is **not FDA-approved**. It's only available inside clinical trials. Anything sold online as "retatrutide" outside a trial is unregulated, and TelosRX does not offer it.

## 2\. Most of the Weight Lost Was Fat

The key paper here is a 2025 body-composition substudy in _The Lancet Diabetes & Endocrinology_. Researchers scanned adults with type 2 diabetes using DXA, a low-dose X-ray that splits the body into fat, lean tissue and bone.

The [published abstract](https://pubmed.ncbi.nlm.nih.gov/40609566/) reports that retatrutide significantly reduced total body fat mass compared with both placebo and dulaglutide. Of 189 people who entered the substudy, 103 finished with scans at baseline and week 36.

So the headline is reassuring. Fat was the main thing that went.

## 3\. Lean Mass Still Fell, in Line With Other Drugs

Retatrutide did not spare lean mass entirely. The substudy authors described the proportion of lean mass lost as similar to other obesity treatments.

The 2025 review lists roughly a third of the weight lost on 12 mg as lean mass at 36 weeks. That sits between the figures reported for semaglutide and tirzepatide. No trial so far shows retatrutide _adding_ muscle on average.

## 4\. "Lean Mass" Is Not the Same as Muscle

This is where many headlines go wrong. DXA lean mass includes muscle, but also water, organs and connective tissue. When you lose weight, some of that non-muscle tissue shrinks too.

So a lean-mass drop overstates pure muscle loss to some degree. It's still a useful warning signal. Our guide to [lean mass vs muscle mass on a GLP-1](https://www.telosrx.com/blogs/glp1/lean-mass-vs-muscle-mass-glp1) explains what scans can and can't tell you.

## 5\. Faster, Bigger Weight Loss Raises the Stakes

Any large calorie deficit costs some lean tissue. That's true with diet alone, surgery or medication. The more weight you lose, the more lean mass you can lose in absolute terms.

The [Phase 2 obesity trial in the New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2301972) reported weight reductions above 20% on the top doses at 48 weeks. At that scale, protecting muscle stops being optional. It becomes part of the plan.

Groups at higher risk include older adults, people who already have low muscle mass, and anyone eating very little protein. Interest in age-related muscle loss is rising for a reason. Muscle gets harder to rebuild with age.

**Retatrutide isn't available outside trials. Tirzepatide is.** TelosRX offers [compounded tirzepatide](https://www.telosrx.com/pages/tirzepatide) through an asynchronous online review. Compounded medications are not FDA-approved, and any prescription is subject to medical approval by a licensed provider.

## 6\. Phase 3 Body-Composition Data Is Still Thin

Lilly's Phase 3 TRIUMPH program is testing retatrutide in larger groups. As of 20 November 2026, we could not find peer-reviewed Phase 3 DXA results that settle the muscle question.

Until those publish, the best evidence is the 36-week substudy above. It was modest in size and enrolled people with type 2 diabetes. Results may differ in people without diabetes. Our [retatrutide vs tirzepatide comparison](https://www.telosrx.com/blogs/glp1/retatrutide-vs-tirzepatide-comparison-glp1) covers what each trial program has published.

## 7\. Protein and Lifting Do the Heavy Lifting

No drug in this class has been shown to protect muscle on its own. What has support is boring and effective: enough protein and regular resistance training.

The 2025 review cites a proposed intake of about 1.5 g of protein per kg of body weight per day during GLP-1 therapy. It also notes that resistance exercise has cut fat-free mass loss by 50% to 95% in calorie-restricted dieting studies. Those are diet studies, not retatrutide trials, but the logic carries over.

## Why the Glucagon Piece Gets Attention

Glucagon is usually known as the hormone that raises blood sugar. In retatrutide, it's paired with GLP-1 and GIP to balance that effect. The interest is in what glucagon does to fat and energy use.

Early research suggests glucagon signaling may raise energy expenditure and help clear liver fat. Some commentators have guessed that this could tilt weight loss further toward fat. So far, the scan data doesn't show a clear muscle advantage from it.

That's a useful reminder. A plausible mechanism is not the same as a measured result. Trial readouts, not theory, should guide what you expect from any new obesity drug.

## What Researchers Still Don't Know

The retatrutide muscle story has real gaps. These are the open questions worth watching as more trials publish:

-   **Muscle quality.** DXA measures quantity. It doesn't show strength or how well muscle works.
-   **Function.** Few GLP-1 trials have tracked grip strength, walking speed or stair climbing.
-   **Longer timelines.** Most body-composition data stops before 18 months.
-   **People without diabetes.** The DXA substudy enrolled adults with type 2 diabetes only.
-   **Older adults.** They have the most to lose from muscle decline and are often underrepresented.
-   **Weight regain.** If weight returns after stopping, it may come back as more fat than muscle.

Until those answers arrive, plan as if muscle protection is your job, not the drug's.

## Strength Matters More Than the Scan

A body scan is a snapshot. Daily strength is the thing you actually live with. Can you carry groceries, climb stairs and get off the floor easily?

Simple at-home checks help. Track how many push-ups or sit-to-stands you can do. Note your grip on heavy bags. If those numbers hold steady while the scale drops, that's a good sign.

## How to Protect Muscle on Any GLP-1 Plan

These habits apply whether you're on tirzepatide, semaglutide or a future triple agonist. Talk them through with your provider before you start.

1.  **Lift two to three times a week.** Squats, rows, presses and carries. Work close to fatigue. Bodyweight moves count.
2.  **Front-load protein.** Eat your protein first at each meal, before appetite fades.
3.  **Spread protein through the day.** Several moderate servings beat one big one.
4.  **Don't over-restrict.** The medication already cuts appetite. Stacking a crash diet on top makes muscle loss more likely.
5.  **Sleep seven to nine hours.** Poor sleep makes recovery and appetite control harder.
6.  **Track more than the scale.** Strength, waist size and occasional body scans tell a fuller story.

Some people ask about supplements. We reviewed the evidence on [HMB for muscle loss on GLP-1](https://www.telosrx.com/blogs/glp1/hmb-for-muscle-loss-glp1-research) separately. Online buzz about "peptides for muscle growth and fat loss" runs well ahead of the human data.

## Warning Signs Worth Reporting

Muscle loss creeps up quietly. Watch for these and message your provider if they show up:

-   Getting weaker on lifts or daily tasks, like stairs or carrying groceries
-   Feeling unusually tired or shaky
-   Struggling to eat enough protein most days
-   Weight dropping much faster than planned

Our list of [signs of muscle loss on GLP-1](https://www.telosrx.com/blogs/glp1/signs-of-muscle-loss-on-glp1) goes deeper.

## What Retatrutide Muscle Loss Means for You Today

If you're weighing a GLP-1 now, retatrutide isn't an option outside a trial. The practical choice is between approved brands and compounded tirzepatide or semaglutide, each with its own trade-offs.

Whatever you choose, the muscle plan looks the same. Protein, resistance training and steady pacing. A licensed provider can help you set that up, subject to medical approval by a licensed provider.

## How TelosRX Fits In

TelosRX is an online-first, asynchronous telehealth service. You complete a private intake on your schedule. A licensed provider reviews it and replies by message, with no live video visit needed.

Options can include compounded tirzepatide and compounded semaglutide. These are not FDA-approved. TelosRX does not supply retatrutide or any investigational drug.

## Frequently Asked Questions

### Does retatrutide cause muscle loss?

Yes, some. In a 2025 DXA substudy of adults with type 2 diabetes, retatrutide cut fat mass far more than placebo or dulaglutide. Lean mass also fell, in a proportion the authors called similar to other obesity treatments. A 2025 review lists about a third of weight lost as lean mass at 36 weeks.

### Does retatrutide cause more muscle loss than tirzepatide?

No direct head-to-head body-composition trial exists. Separate trials report roughly a third of loss as lean mass on retatrutide at 36 weeks and about a quarter on tirzepatide at 72 weeks. Different people, doses and timelines make the numbers hard to compare fairly, so neither drug can be called muscle-sparing.

### Does GLP-1 cause muscle loss?

GLP-1 medicines can lead to some lean mass loss, as does any large weight reduction. Published scans show most weight lost on semaglutide and tirzepatide is fat. The lean share varied from about a quarter to about two-fifths across trials. Protein intake and resistance training are the best-supported ways to limit it.

### Is Ozempic muscle loss different from retatrutide?

Ozempic is semaglutide. In the STEP 1 trial of semaglutide 2.4 mg, roughly 39% of weight lost was lean mass, per a 2025 review. Retatrutide's substudy showed about a third. These came from different trial designs, so the gap may not hold up in a direct comparison.

### Can you build muscle on retatrutide?

No published retatrutide trial shows average gains in lean or muscle mass. Some people may hold or build muscle with heavy resistance training and high protein intake, but that comes from the training, not the drug. Retatrutide remains investigational and is not FDA-approved for any use.

### Is muscle lost on a GLP-1 permanent?

Not necessarily. Muscle responds to training at almost any age, so lost lean tissue can often be rebuilt with resistance exercise and enough protein. It does take time and effort, and it gets slower with age. That's why most clinicians suggest protecting muscle from the start rather than trying to regain it later.

### Is retatrutide FDA-approved?

No. Retatrutide is an investigational drug from Eli Lilly and is only available in clinical trials as of 20 November 2026. Products sold online as retatrutide outside a trial are unregulated. TelosRX does not offer retatrutide. Tirzepatide and semaglutide options are available, subject to provider approval.

_TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._

Start your private evaluation at [TelosRX](https://telosrx.com).

**Tags:** does retatrutide cause muscle loss, GLP-1 muscle loss, lean mass, listicle, retatrutide muscle loss, strength training

---

> Source: [Telos RX](https://www.telosrx.com/blogs/glp1/retatrutide-muscle-loss-research)
